Lipoprotein(a): influence on cardiovascular manifestation;Lipoprotein(a) – Einfluss auf die kardiovaskuläre Manifestation

Clinical Research in Cardiology Supplements

Volumn 10, Issue 1, 2015, Pages 33-38

  Mellwig, K P ^a   Schatton, C ^a   Biermann, B ^a   Kottmann, T ^a   Horstkotte, D ^a   van Buuren, F ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Coronary artery disease; HbA1c; LDL cholesterol; Lipoprotein(a)

Indexed keywords

HEMOGLOBIN A1C; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE COURSE; DISEASE SEVERITY; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; PATHOGENESIS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEX DIFFERENCE; AGED; ARTERIAL OCCLUSIVE DISEASES; BLOOD; CAROTID STENOSIS; COMORBIDITY; FEMALE; GERMANY; INCIDENCE; MALE; MIDDLE AGED; PREVALENCE; REPRODUCIBILITY; RISK FACTOR; SENSITIVITY AND SPECIFICITY;

AGED; ARTERIAL OCCLUSIVE DISEASES; CAROTID STENOSIS; COMORBIDITY; FEMALE; GERMANY; HUMANS; INCIDENCE; LIPOPROTEIN(A); MALE; MIDDLE AGED; PREVALENCE; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 84924968122     PISSN: 18610706     EISSN: 18610714     Source Type: Journal    
DOI: 10.1007/s11789-015-0072-2     Document Type: Article

References (47)

1. Ashfaq F, Goel PK, Sethi R, Khan MI, Ali W, Idris MZ (2013) Lipoprotein(a) levels in relation to severity of coronary artery disease in north indian patients. Heart Views 14:12–16. doi:10.4103/1995-705X.107114HV-14-12 [pii]
2. Berg K (1963) A new serum type system in man –the Lp System. Acta Pathol Microbiol Scand 59:369–382
3. Berg K, Dahlen G, Christophersen B, Cook T, Kjekshus J, Pedersen T (1997) Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study. Clin Genet 52:254–261
4. Bostom AG, Cupples LA, Jenner JL, Ordovas JM, Seman LJ, Wilson PW, Schaefer EJ, Castelli WP (1996) Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. A prospective study. JAMA 276:544–548
5. Buechler C, Ullrich H, Aslanidis C, Bared SM, Lingenhel A, Ritter M, Schmitz G (2003) Lipoprotein (a) downregulates lysosomal acid lipase and induces interleukin-6 in human blood monocytes. Biochim Biophys Acta 1642:25–31 doi:S0167488903000831 [pii]
6. Catalano M, Perilli E, Carzaniga G, Colombo F, Carotta M, Andreoni S (1998) Lp(a) in hypertensive patients. J Hum Hypertens 12:83–89
7. Cremer P, Nagel D, Labrot B, Mann H, Muche R, Elster H, Seidel D (1994) Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Gottingen Risk Incidence and Prevalence Study (GRIPS). Eur J Clin Invest 24:444–453
8. Dahlen GH, Guyton JR, Attar M, Farmer JA, Kautz JA, Gotto AM, Jr (1986) Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation 74:758–765
9. von Eckardstein A Schulte H Cullen P Assmann G (2001) Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk. J Am Coll Cardiol 37:434–439
10. Frohlich J, Dobiasova M, Adler L, Francis M (2004) Gender differences in plasma levels of lipoprotein (a) in patients with angiographically proven coronary artery disease. Physiol Res 53:481–486
11. Gaeta G, Cuomo S, Capozzi G, Foglia MC, Barra S, Madrid A, Stornaiuolo V, Trevisan M (2008) Lipoprotein(a) levels are increased in healthy young subjects with parental history of premature myocardial infarction. Nutr Metab Cardiovasc Dis 18:492–496. doi:S0939–4753(07)00106-8[pii]10.1016/j.numecd.2007.03.006
12. Genest J, Jr, Jenner JL, McNamara JR, Ordovas JM, Silberman SR, Wilson PW, Schaefer EJ (1991) Prevalence of lipoprotein (a) [Lp(a)] excess in coronary artery disease. Am J Cardiol 67:1039–1145. doi:0002-9149(91)90862-F [pii]
13. Genest JJ, McNamara JR, Salem DN, Schaefer EJ (1991) Prevalence of risk factors in men with premature coronary artery disease. Am J Cardiol 67:1185–1189. doi:0002–9149(91)90924-A [pii]
14. Genest J, Jr, McNamara JR, Ordovas JM, Jenner JL, Silberman SR, Anderson KM, Wilson PW, Salem DN, Schaefer EJ (1992) Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormalities in men with premature coronary artery disease. J Am Coll Cardiol 19:792–802. doi:0735-1097(92)90520-W [pii]
15. Genest JJ, Jr, Martin-Munley SS, McNamara JR, Ordovas JM, Jenner J, Myers RH, Silberman SR, Wilson PW, Salem DN, Schaefer EJ (1992) Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation 85:2025–2033
16. Glader CA, Birgander LS, Stenlund H, Dahlen GH (2002) Is lipoprotein(a) a predictor for survival in patients with established coronary artery disease? Results from a prospective patient cohort study in northern Sweden. J Intern Med 252:27–35. aid_997 [pii]
17. Golden SH, Folsom AR, Coresh J, Sharrett AR, Szklo M, Brancati F (2002) Risk factor groupings related to insulin resistance and their synergistic effects on subclinical atherosclerosis: the atherosclerosis risk in communities study. Diabetes 51:3069–3076
18. Hahmann HW, Schätzer-Klotz D, Bunte T (1999) The significance of high levels of lipoprotein(a) compared with etablished risk factors in premature coronary artery disease. Diffrences between men and woman. Atherosclerosis 144:7
19. Imhof A, Rothenbacher D, Khuseyinova N, Hoffmeister A, Maerz W, Nauck M, Scharnagl H, Koenig W, Brenner H (2003) Plasma lipoprotein Lp(a), markers of haemostasis and inflammation, and risk and severity of coronary heart disease. Eur J Cardiovasc Prev Rehabil 10:362–370. doi:10.1097/01.hjr.0000087080.83314.be
20. Jones GT, van Rij AM, Cole J, Williams MJ, Bateman EH, Marcovina SM, Deng M, McCormick SP (2007) Plasma lipoprotein(a) indicates risk for 4 distinct forms of vascular disease. Clin Chem 53:679–685. doi:clinchem.2006.079947 10.1373/clinchem.2006.079947[pii]
21. Kamstrup PR, Benn M, Tybjaerg-Hansen A (2008) Extreme lipoprotein(a) levels and risk of myocardial infarction: th Copenhagen City HEART sTUDY. Circulation 8
22. Kamstrup PR, Benn M, Tybjaerg-Hansen A, Nordestgaard BG (2008) Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. Circulation 117:176–184. doi:10.1161/CIRCULATIONAHA.107.715698
23. Kamstrup PR, Tybjaerg-Hansen A, Steffenssen R (2009) Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 301:2331–2339
24. Klausen IC, Sjol A, Hansen PS, Gerdes LU, Moller L, Lemming L, Schroll M, Faergeman O (1997) Apolipoprotein(a) isoforms and coronary heart disease in men: a nested case-control study. Atherosclerosis 132:77–84. doi:S0021-9150(97)00071-3 [pii]
25. Leebmann J, Roeseler E, Julius U, Heigl F, Spitthoever R, Heutling D, Breitenberger P, Maerz W, Lehmacher W, Heibges A, Klingel R (2013) Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study. Circulation 128:2567–2576. doi:10.1161/circulationaha.113.002432
26. Luc G, Bard JM, Arveiler D, Ferrieres J, Evans A, Amouyel P, Fruchart JC, Ducimetiere P (2002) Lipoprotein (a) as a predictor of coronary heart disease: the PRIME Study. Atherosclerosis 163:377–384. doi:S0021915002000266 [pii]
27. Mestre C, Grand A, Fournis Y, Mamelle N, Landrault E, Cambrillat N (1998) [The importance of lipoprotein(a) as a predictive factor of coronary atherosclerosis]. Presse Med 27:849–854
28. Murase T, Okubo M, Amemiya-Kudo M, Hiraga T, Oka J, Shimada M, Igarashi T (2007) Impact of markedly elevated serum lipoprotein(a) levels (> or = 100 mg/dL) on the risk of coronary heart disease. Metabolism 56:1187–1191. doi:S0026-0495(07)00151-5 [pii] 10.1016/j.metabol.2007.04.015
29. Murase T, Okubo M, Amemiya-Kudo M, Ebara T, Mori Y (2008) Impact of elevated serum lipoprotein (a) concentrations on the risk of coronary heart disease in patients with type 2 diabetes mellitus. Metabolism 57:791–795
30. Nicholls SJ, Tang WH, Scoffone H, Brennan DM, Hartiala J, Allayee H, Hazen SL (2010) Lipoprotein(a) levels and long-term cardiovascular risk in the contemporary era of statin therapy. J Lipid Res 51:3055–3061
31. Nordestgaard BG, Chapman MJ, Ray K, Boren J, Andreotti F, Watts GF, Ginsberg H, Amarenco P, Catapano A, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Reiner Z, Taskinen MR, Tokgozoglu L, Tybjaerg-Hansen A, European Atherosclerosis Society Consensus P (2010) Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 31:2844–2853. doi:10.1093/eurheartj/ehq386
32. Onat A, Hergenc G, Ozhan H, Kaya Z, Bulur S, Ayhan E, Can G (2008) Lipoprotein(a) is associated with coronary heart disease independent of metabolic syndrome. Coron Artery Dis 19:125–131
33. Ornek E, Murat S, Duran M, Turfan M, Kurtul A, Demircelik MB, Vatankulu MA, Ocek H, Akdemir R (2011) The relationship between lipoprotein(a) and coronary artery disease, as well as its variable nature following myocardial infarction. Clin Invest Med 34:E14–20
34. Pineda J, Marin F, Marco P, Roldan V, Valencia J, Ruiz-Nodar JM, Sogorb F, Lip GY (2009) Premature coronary artery disease in young (age < 45) subjects: interactions of lipid profile, thrombophilic and haemostatic markers. Int J Cardiol 136:222–225. doi:S0167–5273(08)00598-6 [pii]10.1016/j.ijcard.2008.04.020
35. Ridker PM, Hennekens CH, Stampfer MJ (1993) A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA 270:2195–2199
36. Salomaa V, Rasi V, Pekkanen J, Vahtera E, Jauhiainen M, Vartiainen E, Myllyla G, Ehnholm C (1994) Haemostatic factors and prevalent coronary heart disease; the FINRISK Haemostasis Study. Eur Heart J 15:1293–1299
37. Sawabe M, Tanaka N, Nakahara K, Hamamatsu A, Chida K, Arai T, Harada K, Inamatsu T, Ozawa T, Naka MM, Matsushita S (2009) High lipoprotein(a) level promotes both coronary atherosclerosis and myocardial infarction: a path analysis using a large number of autopsy cases. Heart 95:1997–2002. doi:hrt.2008.160879 [pii]10.1136/hrt.2008.160879
38. Schaefer EJ, Lamon-Fava S, Jenner JL, McNamara JR, Ordovas JM, Davis CE, Abolafia JM, Lippel K, Levy RI (1994) Lipoprotein(a) levels and risk of coronary heart disease in men. The lipid Research Clinics Coronary Primary Prevention Trial. JAMA 271:999–1003
39. Schreiner PJ (1994) Lipoprotein(a) as a risk factor for preclinical atherosclerotic disease in a biracial cohort: the Atherosclerosis Risk in Communities (ARIC) Study. Chem Phys Lipids 67–68:405–410
40. Schwartzman RA, Cox ID, Poloniecki J, Crook R, Seymour CA, Kaski JC (1998) Elevated plasma lipoprotein(a) is associated with coronary artery disease in patients with chronic stable angina pectoris. J Am Coll Cardiol 31:1260–1266
41. Seed M, Ayres KL, Humphries SE, Miller GJ (2001) Lipoprotein (a) as a predictor of myocardial infarction in middle-aged men. Am J Med 110:22–27
42. Seman LJ, DeLuca C, Jenner JL, Cupples LA, McNamara JR, Wilson PW, Castelli WP, Ordovas JM, Schaefer EJ (1999) Lipoprotein(a)-cholesterol and coronary heart disease in the Framingham Heart Study. Clin Chem 45:1039–1046
43. Shai I, Rimm EB, Hankinson SE, Cannuscio C, Curhan G, Manson JE, Rifai N, Stampfer MJ, Ma J (2005) Lipoprotein (a) and coronary heart disease among women: beyond a cholesterol carrier? Eur Heart J 26:1633–1639. doi:ehi222 [pii] 10.1093/eurheartj/ehi222
44. Shai I, Schulze MB, Manson JE, Stampfer MJ, Rifai N, Hu FB (2005) A prospective study of lipoprotein(a) and risk of coronary heart disease among women with type 2 diabetes. Diabetologia 48:1469–1476. doi:10.1007/s00125-005-1814-3
45. Starkman HS, Cable G, Hala V, Hecht H, Donnelly CM (2003) Delineation of prevalence and risk factors for early coronary artery disease by electron beam computed tomography in young adults with type 1 diabetes. Diabetes Care 26:433–436
46. Thomas HP, Steinhagen-Thiessen E (2003) [Lipoprotein(a): Aspects of pathophysiology, epidemiology and treatment]. Z Kardiol 92:III53–III58
47. Tselepis AD, Elisaf M, Goudevenos J, Tselegaridis T, Bairaktari E, Siamopoulos KC, Sideris D (1996) Lipid profile in patients with microvascular angina. Eur J Clin Invest 26:1150–1155